| Literature DB >> 28886703 |
Michelle R Kaminski1, Anita Raspovic2, Lawrence P McMahon3, Katrina A Lambert4, Bircan Erbas4, Peter F Mount5, Peter G Kerr6, Karl B Landorf2,7.
Abstract
BACKGROUND: Adults on dialysis are at increased risk of foot ulceration, which commonly precedes more serious lower limb complications, including amputation. Limited data exist regarding the prevalence and factors associated with foot disease in this population. Hence, this study set out to investigate factors associated with foot ulceration and amputation in a dialysis cohort.Entities:
Keywords: Amputation; Chronic kidney failure; Dialysis; Foot ulcer; Risk factors
Mesh:
Year: 2017 PMID: 28886703 PMCID: PMC5591526 DOI: 10.1186/s12882-017-0711-6
Source DB: PubMed Journal: BMC Nephrol ISSN: 1471-2369 Impact factor: 2.388
Fig. 1Flow of study participants
Participant characteristics – data are n (%), unless otherwise stated
| Current foot ulceration | Lower extremity amputation | ||||||
|---|---|---|---|---|---|---|---|
| Total | Yes | No |
| Yes | No |
| |
| Mean age (SD), | 67.5 (13.2) | 69.0 (10.3) | 67.3 (13.5) | 0.33 | 65.4 (11.2) | 67.7 (13.4) | 0.25 |
| Male sex | 291 (64.7) | 36 (80.0) | 255 (63.0) | 0.035* | 37 (80.4) | 254 (62.9) | 0.028* |
| Mean body mass index (SD), | 28.2 (6.6) | 29.1 (6.5) | 28.1 (6.6) | 0.30 | 30.4 (6.3) | 27.9 (6.6) | 0.014* |
| Current smoking | 54 (12.0) | 5 (11.1) | 49 (12.1) | 1.00 | 5 (10.9) | 49 (12.1) | 0.99 |
| Living alone | 75 (16.7) | 6 (13.3) | 69 (17.0) | 0.67 | 10 (21.7) | 65 (16.1) | 0.44 |
| Ethnicity | |||||||
| Indigenous Australian | 4 (0.9) | 0 (0) | 4 (1.0) | 1.00 | 1 (2.2) | 3 (0.7) | 0.88 |
| English | 85 (18.9) | 9 (20) | 76 (18.8) | 1.00 | 12 (26.1) | 73 (18.1) | 0.94 |
| European | 194 (43.1) | 16 (35.6) | 178 (44.0) | 0.36 | 14 (30.4) | 180 (44.6) | 0.60 |
| American | 4 (0.9) | 0 (0) | 4 (1.0) | 1.00 | 0 (0) | 4 (1.0) | 1.00 |
| African | 14 (3.1) | 1 (2.2) | 13 (3.2) | 1.00 | 2 (4.3) | 12 (3.0) | 0.95 |
| Asian | 67 (14.9) | 5 (11.1) | 62 (15.3) | 0.60 | 1 (2.2) | 66 (16.3) | 0.88 |
| Pacific Islander | 29 (6.4) | 3 (6.7) | 26 (6.4) | 1.00 | 5 (10.9) | 24 (5.9) | 0.33 |
| Othera | 53 (11.8) | 11 (24.4) | 42 (10.4) | 0.011* | 11 (23.9) | 42 (10.4) | 0.159 |
| Cause of ESRD | |||||||
| Diabetes mellitus | 180 (40.0) | 37 (82.2) | 143 (35.3) | <0.001* | 42 (91.3) | 138 (34.2) | 0.98 |
| Hypertension | 28 (6.2) | 1 (2.2) | 27 (6.7) | 0.40 | 1 (2.2) | 27 (6.7) | 0.82 |
| Glomerulonephritis | 97 (21.6) | 2 (4.4) | 95 (23.5) | 0.006* | 0 (0) | 97 (24.0) | 0.88 |
| Polycystic kidney disease | 22 (4.9) | 1 (2.2) | 21 (5.2) | 0.61 | 1 (2.2) | 21 (5.2) | 0.104 |
| Reflux | 19 (4.2) | 1 (2.2) | 18 (4.4) | 0.76 | 1 (2.2) | 18 (4.5) | 0.67 |
| Renovascular disease | 10 (2.2) | 0 (0) | 10 (2.5) | 0.59 | 1 (2.2) | 9 (2.2) | 0.58 |
| Vasculitis | 9 (2.0) | 0 (0) | 9 (2.2) | 0.65 | 0 (0) | 9 (2.2) | 0.64 |
| Unknown | 15 (3.3) | 1 (2.2) | 14 (3.5) | 1.00 | 0 (0) | 15 (3.7) | 0.37 |
| Other | 70 (15.6) | 2 (4.4) | 68 (16.8) | 0.05 | 0 (0) | 70 (17.3) | 0.88 |
| Dialysis treatment | |||||||
| Hemodialysis | 423 (94.0) | 42 (93.3) | 381 (94.1) | 1.00 | 43 (93.5) | 380 (94.1) | 0.41 |
| Peritoneal dialysis | |||||||
| CAPD | 9 (2.0) | 0 (0) | 9 (2.2) | 0.65 | 0 (0) | 9 (2.2) | 0.64 |
| APD | 18 (4.0) | 3 (6.7) | 15 (3.7) | 0.58 | 3 (6.5) | 15 (3.7) | 0.79 |
| Median duration of dialysis (IQR), | 36.9 (16.6 to 70.1) | 37.5 (20.0 to 64.1) | 36.8 (16.5 to 71.8) | 0.91 | 38.3 (17.7 to 72.6) | 36.6 (16.6 to 69.5) | 0.77 |
| Diabetes mellitus | 226 (50.2) | 39 (86.7) | 187 (46.2) | <0.001* | 43 (93.5) | 183 (45.3) | <0.001* |
| Type 1 | 13 (5.8) | 4 (10.3) | 9 (4.8) | 0.34 | 7 (15.2) | 6 (1.5) | 0.003* |
| Type 2 | 213 (94.2) | 35 (89.7) | 178 (95.2) | 0.34 | 36 (78.3) | 177 (43.8) | 0.003* |
| Mean duration (SD), | 256.3 (152.6) | 348.8 (167.6) | 237.0 (142.3) | <0.001* | 301.8 (163.1) | 245.6 (148.5) | 0.043* |
| Retinopathy | 132 (29.3) | 28 (62.2) | 104 (25.7) | <0.001* | 32 (69.6) | 100 (24.8) | <0.001* |
| Known peripheral neuropathyb | 70 (15.6) | 20 (44.4) | 50 (12.3) | <0.001* | 26 (56.5) | 44 (10.9) | <0.001* |
| Known peripheral arterial diseaseb | 79 (17.6) | 27 (60.0) | 52 (12.8) | <0.001* | 31 (67.4) | 48 (11.9) | <0.001* |
| Lower extremity revascularization procedure | 35 (7.8) | 22 (48.9) | 13 (3.2) | <0.001* | 20 (43.5) | 15 (3.7) | <0.001* |
| Hypertension (requiring medication) | 360 (80.0) | 36 (80.0) | 324 (80.0) | 1.00 | 40 (87.0) | 320 (79.2) | 0.29 |
| Dyslipidemia | 301 (66.9) | 38 (84.4) | 263 (64.9) | 0.013* | 39 (84.8) | 262 (64.9) | 0.011* |
| Ischemic heart disease | 263 (58.4) | 36 (80.0) | 227 (56.0) | 0.003* | 33 (71.7) | 230 (56.9) | 0.076 |
| Congestive cardiac failure | 122 (27.1) | 18 (40.0) | 104 (25.7) | 0.061 | 15 (32.6) | 107 (26.5) | 0.48 |
| Cerebrovascular disease | 104 (23.1) | 19 (42.2) | 85 (21.0) | 0.003* | 15 (32.6) | 89 (22.0) | 0.153 |
| Osteoarthritis | 192 (42.7) | 17 (37.8) | 175 (43.2) | 0.60 | 15 (32.6) | 177 (43.8) | 0.194 |
| Inflammatory arthritis | 183 (40.7) | 14 (31.1) | 169 (41.7) | 0.22 | 13 (28.3) | 170 (42.1) | 0.099 |
| Median C-reactive protein (SD), | 7.33 (2.83 to 19.67) | 10.00 (4.82 to 43.83) | 6.95 (2.67 to 18.08) | 0.011* | 10.89 (4.44 to 36.88) | 6.90 (2.67 to 18.50) | 0.026* |
| Mean serum albumin (SD), | 33.73 (3.94) | 31.12 (4.76) | 34.01 (3.74) | <0.001* | 32.50 (4.32) | 33.86 (3.88) | 0.045 |
| Mean total calcium (SD), | 2.20 (0.14) | 2.15 (0.13) | 2.20 (0.14) | 0.008* | 2.21 (0.12) | 2.20 (0.14) | 0.69 |
| Mean phosphate (SD), | 1.55 (0.38) | 1.64 (0.39) | 1.54 (0.38) | 0.135 | 1.59 (0.41) | 1.55 (0.38) | 0.53 |
| Median parathyroid hormone (SD), | 29.58 (18.04 to 45.84) | 28.03 (20.70 to 43.02) | 29.77 (17.38 to 46.25) | 0.83 | 28.52 (21.56 to 50.24) | 29.65 (17.38 to 45.43) | 0.54 |
| Mean glycated hemoglobin (SD), | 6.14 (1.31) | 6.89 (1.24) | 6.05 (1.29) | <0.001* | 6.98 (1.36) | 6.03 (1.27) | <0.001* |
| Median hemoglobin (IQR), | 111.33 (102.92 to 117.67) | 108.00 (99.50 to 115.83) | 111.67 (103.67 to 117.67) | 0.060 | 108.50 (99.25 to 115.25) | 111.67 (103.67 to 117.67) | 0.080 |
| Mean SF-36v2® PCS (SD) | 38.14 (10.70) | 33.08 (8.92) | 38.71 (10.74) | 0.001* | 33.16 (9.93) | 38.71 (10.65) | 0.001* |
| Mean SF-36v2® MCS (SD) | 48.55 (11.40) | 47.08 (13.96) | 48.71 (11.09) | 0.45 | 47.11 (13.56) | 48.71 (11.14) | 0.44 |
| Previous foot ulceration | 97 (21.6) | 32 (71.1) | 65 (16.0) | <0.001* | 44 (95.7) | 53 (13.1) | <0.001* |
| Current foot ulceration | 45 (10.0) | 45 (100.0) | N/A | N/A | 26 (56.5) | 19 (4.7) | <0.001* |
| Lower extremity amputation | 46 (10.2) | 26 (57.8) | 20 (4.9) | <0.001* | 46 (100) | N/A | N/A |
| Minor | 39 (8.7) | 22 (48.9) | 17 (4.2) | <0.001* | 39 (84.8) | ||
| Major | 12 (2.7) | 8 (17.8) | 4 (1.0) | <0.001* | 12 (26.1) | ||
| Combination | 5 (1.1) | 4 (8.9) | 1 (0.2) | <0.001* | 5 (10.9) | ||
*Significant difference between ‘foot ulceration/amputation’ and ‘no foot ulceration/amputation’ groups, p < 0.05. SD Standard deviation. a‘Ethnicity other’ were for participants that identified themselves as ‘Australian’ (excluding Indigenous Australians). ESRD End-stage renal disease. CAPD Continuous ambulatory peritoneal dialysis. APD Automated peritoneal dialysis. IQR Interquartile range. bKnown peripheral neuropathy/known peripheral arterial disease were defined as a history of peripheral neuropathy/peripheral arterial disease documented in the medical records. cAn average of the three latest laboratory test values was collected. dMaximum missing data were for glycated hemoglobin involving 39 participants overall (8.7%). Missing data were for glycated hemoglobin (n = 39) and C-reactive protein (n = 3). SF-36v2® = Short-Form-36 version 2.0. PCS Physical component score. MCS Mental component score. N/A Not applicable
Foot examination, foot-health care behaviors and podiatry attendance – data are n (%), unless otherwise specified
| Foot ulceration | Lower extremity amputation | ||||||
|---|---|---|---|---|---|---|---|
| Total | Yes | No |
| Yes | No |
| |
| Peripheral neuropathya | 228 (50.7) | 43 (95.6) | 185 (45.7) | <0.001* | 44 (95.7) | 184 (45.5) | <0.001* |
| Peripheral arterial diseaseb | 236 (52.4) | 42 (93.3) | 194 (47.9) | <0.001* | 39 (84.8) | 197 (48.8) | <0.001* |
| Arterial calcification | 184 (40.9) | 20 (44.4) | 164 (40.5) | 0.73 | 21 (45.7) | 163 (40.3) | 0.592 |
| Foot deformity | 341 (75.8) | 39 (86.7) | 302 (74.6) | 0.107 | 42 (91.3) | 299 (74.0) | 0.016* |
| Limited range of motion of first MTPJc | 421 (93.6) | 39 (86.7) | 382 (94.3) | 0.29 | 38 (82.6) | 383 (94.8) | 0.30 |
| Median peak plantar pressure (IQR), | |||||||
| Total left footd | 1.74 (1.50 to 2.06) | 2.00 (1.74 to 2.40) | 1.73 (1.50 to 2.04) | 0.007* | 2.02 (1.76 to 2.36) | 1.73 (1.50 to 2.03) | 0.002* |
| Total right footd | 1.72 (1.50 to 2.09) | 2.11 (1.68 to 2.42) | 1.71 (1.49 to 2.05) | 0.002* | 2.09 (1.80 to 2.42) | 1.71 (1.49 to 2.05) | 0.001* |
| Skin pathology | 395 (87.8) | 42 (93.3) | 353 (87.2) | 0.34 | 43 (93.5) | 352 (87.1) | 0.31 |
| Nail pathology | 319 (70.9) | 37 (82.2) | 282 (69.6) | 0.112 | 34 (73.9) | 285 (70.5) | 0.76 |
| Inappropriate footwear | 297 (66.0) | 25 (55.6) | 272 (67.2) | 0.164 | 21 (45.7) | 276 (68.3) | 0.004* |
| Poor foot-health care | 136 (30.2) | 10 (22.2) | 126 (31.1) | 0.289 | 7 (15.2) | 129 (31.9) | 0.030* |
| Podiatry attendance, | 223 (49.6) | 36 (80.0) | 187 (46.2) | <0.001* | 36 (78.3) | 187 (46.3) | <0.001* |
*Significant difference between ‘foot ulceration/amputation’ and ‘no foot ulceration/amputation’ groups, p < 0.05. MTPJ Metatarsophalangeal joint. aPeripheral neuropathy was defined as documentation of known peripheral neuropathy in the medical records; monofilament score < 3/3 (either foot); and/or vibration perception threshold >25 V (either foot). bPeripheral arterial disease was defined as documentation of known peripheral arterial disease in the medical records and/or history of lower extremity revascularization procedure; absence of ≥2 pedal pulses; toe-brachial pressure index ≤0.6 (either foot); and/or ankle-brachial pressure index ≤0.9. cMaximum missing data were for left peak plantar pressure involving 56 participants overall (12.4%). Missing data were for limited range of motion of first MTPJ (left, n = 25; right, n = 15) and peak plantar pressures (left, n = 56; right, n = 55). dData presented are of the total foot and do not include any specific regions (e.g. hallux, 1st MTPJ, etc.). IQR Interquartile range
Multivariate logistic regression analysis for factors associated with foot ulceration – data are n (%), unless otherwise specified
| Foot ulceration | Multivariate logistic regression analysis | ||||
|---|---|---|---|---|---|
| Risk Factor | Yes | No | |||
|
| 45 | 405 | aOR | 95% CI |
|
| Previous amputation | 26 (57.8) | 20 (4.9) | 10.19 | 3.14 to 33.07 | <0.001* |
| Peripheral arterial disease | 42 (93.3) | 194 (47.9) | 6.16 | 1.47 to 25.80 | 0.013* |
| Mean serum albumin (SD), | 31.12 (4.76) | 34.01 (3.74) | 0.87 | 0.78 to 0.96 | 0.008* |
| Mean total calcium (SD), | 2.15 (0.13) | 2.20 (0.14) | 0.05 | 0.00 to 1.41 | 0.080 |
| Peripheral neuropathy | 43 (95.6) | 185 (45.7) | 5.02 | 0.97 to 26.02 | 0.055 |
aOR Adjusted odds ratio. CI Confidence interval. *Significant association, p < 0.05. SD Standard deviation. The final multivariate model controlled for the following confounding variables: age, sex, living alone, dialysis duration, diabetes mellitus, serum phosphate, previous foot ulceration and podiatry attendance
Multivariate logistic regression analysis for factors associated with amputation – data are n (%), unless otherwise specified
| Lower extremity amputation | Multivariate logistic regression analysis | ||||
|---|---|---|---|---|---|
| Risk Factor | Yes | No | |||
|
| 46 | 404 | aOR | 95% CI |
|
| Previous foot ulceration | 44 (95.7) | 53 (13.1) | 167.24 | 23.22 to 1204.49 | <0.001* |
| Current foot ulceration | 26 (56.5) | 19 (4.7) | 7.49 | 1.89 to 29.69 | 0.004* |
| Foot deformity | 42 (91.3) | 299 (74.0) | 15.28 | 2.23 to 104.55 | 0.005* |
| Diabetes mellitus | 43 (93.5) | 183 (45.3) | 5.28 | 0.22 to 129.47 | 0.31 |
| Osteoarthritis | 15 (32.6) | 177 (43.8) | 0.26 | 0.07 to 1.03 | 0.055 |
aOR Adjusted odds ratio. CI Confidence interval. *Significant association, p < 0.05. The final multivariate model controlled for the following confounding variables: age, sex, physical component score, dialysis duration, retinopathy, ischemic heart disease, C-reactive protein, serum albumin, serum phosphate, glycated hemoglobin, peripheral neuropathy, peripheral arterial disease, inappropriate/ill-fitting footwear, nail pathology, and podiatry attendance